
"I am glad that taking part in a trial might help others on their own cancer journey.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This study is looking at navitoclax on its own or together with ruxolitinib for people who have myelofibrosis.
Myelofibrosis is a rare blood disorder. It causes scarring of the bone marrow so it can’t make blood cells properly.
Myelofibrosis can develop without having had any other medical condition. This is called primary myelofibrosis. It can also develop in people who have previous blood and bone marrow conditions such as polycythaemia vera or thrombocythaemia. This is called secondary myelofibrosis. This study is for people with either primary or secondary myelofibrosis.
There are a number of different treatments for myelofibrosis. These might include targeted drugs such as ruxolitinib, low dose chemotherapy or supportive care.
You usually have ruxolitinib to improve symptoms of myelofibrosis such as an enlarged . But it doesn’t always work or it stops working. So, researchers are looking at having it alongside another drug called navitoclax. They want to see if this can improve response to treatment.
Navitoclax blocks the functions of a protein found in myelofibrosis cells. This causes these abnormal cells to die.
There is some early research suggesting that combining navitoclax with ruxolitinib might help people with myelofibrosis. It might help people who have had ruxolitinib but it hasn't worked. This is the first study in people with myelofibrosis who will take both drugs together.
The aims of this study are to:
The following bullet points list the entry conditions for this study. Talk to your doctor or the study team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this study if all of the following apply. You:
Who can’t take part
You cannot join this study if any of these apply.
Myelofibrosis or cancer related
You:
Medical conditions
You:
Other
You:
This is a phase 2 study. The study team hope about 164 people will take part in the study including 23 from the UK.
There are 3 different active groups (cohorts) currently active in this trial. Two groups have ruxolitinib and navitoclax. And one group has navitoclax on its own.
The study team can tell you more about which treatment you’ll have when you join the trial.
Ruxolitinib is a tablet. You take it twice a day, every day.
Navitoclax is a tablet. You take it once a day, every day. You start on a dose that is selected by your study doctors. Your doctor might reduce or adjust the dose, if necessary. This is based on your blood counts or any side effects you may have.
You have treatment for as long as it is working and the side effects aren’t too bad.
Samples for research
The researchers will ask to take samples of your when you have a bone marrow test. They will also ask to take extra blood tests as part of this study. The researchers plan to:
They will also ask you to take part in a research project. You don’t have to take part in this if you don’t want to. You can still take part in the study.
Quality of life
The study team will ask you to fill out questionnaires before you start treatment and at a few other set times during treatment. The questionnaire will ask about side effects and how you’ve been feeling. This is called a study.
You’ll see a doctor and have some tests before you start treatment. The tests include:
You go to hospital:
At each visit, you see the doctor for a check and blood tests. You have a bone marrow test and MRI every 3 months for up to 2 years
You stop treatment if your myelofibrosis gets worse. You see the study doctor a month later for a check up. Your doctor will discuss other treatment options with you.
You see the study doctor every 3 months for a check up and an MRI scan if you stopped treatment but your myelofibrosis hasn’t got worse. You continue with these visits until your myelofibrosis gets worse or you start another treatment.
The study team follow you up for 5 years. They might see you at a routine hospital appointment, phone you, or check your medical notes to see how you are getting on.
Having navitoclax and ruxolitinib is a new treatment. So, there might be some side effects we don’t know about yet. The study team will monitor you during the time you have treatment and you’ll have a number to call if you are worried about anything.
The most common side effects of navitoclax are:
The following side effects may happen with ruxolitinib and are very common (may affect more than 10 in 100 people). They include:
Both navitoclax and ruxolitinib can lower the number of in your blood. You should notify your doctor if you have any bleeding or bruising. You have regular blood tests so the doctor can check your platelets.
We have more information about ruxolitinib.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Claire Harrison
AbbVie
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
"I am glad that taking part in a trial might help others on their own cancer journey.”